Marco Valgimigli

Marco Valgimigli's AcademicInfluence.com Rankings

Marco Valgimigli

Chemistry

#1950

World Rank

#2778

Historical Rank

Physical Chemistry

#191

World Rank

#225

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Marco Valgimigli's Degrees

PhD Chemistry University of Bologna
Masters Chemistry University of Bologna
Bachelors Chemistry University of Bologna

Why Is Marco Valgimigli Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Marco Valgimigli's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012) (7528)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). (2018) (6316)
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). (2011) (5496)
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. (2013) (3723)
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). (2020) (3378)
2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous (2014) (3302)
Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium (2011) (3111)
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. (2020) (3083)
[2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. (2016) (2910)
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 (2020) (2362)
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 (2020) (2362)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. (2018) (1802)
2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca (2014) (1551)
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. (2007) (1078)
Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial (2015) (1004)
[2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018) (913)
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. (2012) (718)
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials (2017) (697)
[2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.] (2018) (669)
Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial (2012) (602)
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (2014) (550)
Diagnostic performance of multislice spiral computed tomography of coronary arteries as compared with conventional invasive coronary angiography: a meta-analysis. (2006) (492)
Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial (2012) (432)
CD34+ and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive Heart Failure (2004) (412)
In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. (2005) (409)
Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. (2011) (402)
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial (2019) (401)
Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. (2015) (386)
Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. (2007) (367)
Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials. (2016) (365)
Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease: Insights From the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital Registries (RESEARCH and T-SEARCH) (2005) (353)
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. (2015) (342)
Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. (2011) (338)
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. (2015) (327)
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. (2015) (324)
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. (2005) (322)
Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. (2007) (308)
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. (2019) (302)
[2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation]. (2015) (300)
Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention (2019) (293)
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. (2015) (288)
[2014 ESC/EACTS Guidelines on myocardial revascularization]. (2014) (281)
Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. (2016) (281)
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. (2019) (272)
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk (2019) (266)
International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies (2017) (264)
Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. (2008) (262)
The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. (2005) (258)
Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. (2006) (256)
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. (2011) (254)
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. (2015) (248)
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials (2015) (243)
European expert consensus on rotational atherectomy. (2015) (239)
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. (2005) (229)
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury (2011) (229)
Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance (2009) (226)
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. (2018) (223)
Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. (2013) (218)
A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. (2008) (213)
Favorable Long-Term Outcome After Drug-Eluting Stent Implantation in Nonbifurcation Lesions That Involve Unprotected Left Main Coronary Artery: A Multicenter Registry (2007) (212)
Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials (2014) (210)
Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Sten (2006) (206)
2014 ESC/EACTS guidelines on myocardial revascularization. (2015) (202)
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial (2016) (200)
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. (2015) (199)
Tumor Necrosis Factor-&agr; Receptor 1 Is a Major Predictor of Mortality and New-Onset Heart Failure in Patients With Acute Myocardial Infarction: The Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) Study (2005) (194)
A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: the AVIO trial. (2013) (192)
2014 ESC/EACTS guidelines on myocardial revascularization. (2015) (190)
Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry. (2008) (187)
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis (2014) (184)
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European (2018) (183)
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial (2018) (181)
Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. (2019) (180)
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients (2017) (165)
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients wit (2012) (164)
From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. (2008) (163)
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. (2004) (162)
Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. (2015) (162)
Multislice Spiral Computed Tomography for the Evaluation of Stent Patency After Left Main Coronary Artery Stenting: A Comparison With Conventional Coronary Angiography and Intravascular Ultrasound (2006) (160)
Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. (2019) (160)
PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (2011) (160)
Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. (2012) (159)
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis (2014) (157)
Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial (2016) (157)
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention (2018) (156)
Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. (2006) (154)
Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study (2006) (153)
Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Me (2011) (151)
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. (2011) (148)
Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. (2008) (147)
Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: A long‐term prospective study (1999) (147)
Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. (2012) (139)
Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. (2012) (139)
Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials (2013) (134)
Coronary artery remodelling is related to plaque composition (2005) (133)
Transradial coronary catheterization and intervention across the whole spectrum of Allen test results. (2014) (131)
Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX. (2017) (131)
Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. (2016) (129)
Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. (2015) (128)
Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials (2019) (127)
Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. (2013) (126)
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. (2009) (125)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2017) (124)
Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. (2007) (124)
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. (2021) (124)
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplas (2014) (120)
Excimer Laser LEsion modification to expand non-dilatable stents: the ELLEMENT registry. (2014) (118)
Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry. (2012) (117)
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. (2010) (117)
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). (2013) (117)
Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS). (2006) (116)
Sirolimus-eluting versus paclitaxel-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: a combined RESEARCH and T-SEARCH long-term analysis. (2006) (115)
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. (2010) (113)
CD 34 and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive Heart Failure (2004) (112)
Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. (2008) (111)
Left ventricular unloading and concomitant total cardiac output increase by the use of percutaneous impella recover LP 2.5 assist device during high‐risk coronary intervention (2005) (110)
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial (2019) (110)
Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. (2007) (105)
Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. (2009) (103)
Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radio frequency data analysis, is related to clinical presentation. (2006) (102)
Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. (2017) (100)
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. (2016) (99)
Oxidative Stress EPR Measurement in Human Liver by Radical-probe Technique. Correlation with Etiology, Histology and Cell Proliferation (2002) (98)
Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitropruss (2013) (98)
The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. (2017) (97)
Comparison of early outcome of percutaneous coronary intervention for unprotected left main coronary artery disease in the drug-eluting stent era with versus without intravascular ultrasonic guidance. (2005) (97)
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study (2017) (96)
Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. (2007) (96)
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials (2021) (96)
Angiographic and Optical Coherence Tomography Insights Into Bioresorbable Scaffold Thrombosis (2015) (95)
Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted Fro (2014) (94)
Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs (2018) (91)
Role for Substance P–Based Nociceptive Signaling in Progenitor Cell Activation and Angiogenesis During Ischemia in Mice and in Human Subjects (2012) (89)
Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. (2003) (89)
Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. (2017) (88)
Evaluation of the safety and efficacy of an edoxaban‐based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST‐AF PCI trial (2018) (86)
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial (2016) (86)
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. (2019) (84)
"Full metal jacket" (stented length > or =64 mm) using drug-eluting stents for de novo coronary artery lesions. (2005) (84)
Guía ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST (2017) (83)
Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention: An International Consensus Paper. (2019) (82)
The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. (2014) (80)
Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis (2014) (80)
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. (2021) (79)
Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis. (2006) (78)
Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous (2013) (78)
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) t (2015) (78)
Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. (2020) (77)
A patient-level pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. (2011) (75)
Distance from the ostium as an independent determinant of coronary plaque composition in vivo: an intravascular ultrasound study based radiofrequency data analysis in humans. (2006) (75)
Plaque composition and its relationship with acknowledged shear stress patterns in coronary arteries. (2006) (73)
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. (2019) (72)
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. (2019) (72)
Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). (2005) (70)
Validation of Bleeding Risk Criteria (ARC-HBR) in Patients Undergoing Percutaneous Coronary Intervention and Comparison with Contemporary Bleeding Risk Scores. (2020) (69)
A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial. (2016) (69)
Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. (2013) (69)
Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome. (2015) (69)
Serum From Patients With Acute Coronary Syndromes Displays a Proapoptotic Effect on Human Endothelial Cells: A Possible Link to Pan-Coronary Syndromes (2003) (69)
Incremental Value of the CRUSADE, ACUITY, and HAS‐BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy (2015) (69)
Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplas (2010) (68)
Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment–Elevation Myocardial Infarction and Multivessel Disease (2018) (67)
Single-vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era. Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam C (2006) (67)
Poor response to clopidogrel: current and future options for its management (2010) (66)
A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More? (2016) (65)
Stent Thrombosis in Patients with Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. (2019) (65)
Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial. (2016) (64)
Current use of intracoronary imaging in interventional practice - Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. (2018) (63)
Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis. (2016) (63)
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2. (2018) (62)
Tissue Factor and Coagulation Factor VII Levels During Acute Myocardial Infarction: Association With Genotype and Adverse Events (2006) (62)
Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. (2018) (60)
Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for the design of longitudinal studies (2006) (60)
Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials (2016) (59)
Thrombo-embolic prevention after transcatheter aortic valve implantation (2017) (58)
Safety of optical coherence tomography in daily practice: a comparison with intravascular ultrasound (2016) (58)
Measurement of oxidative stress in human liver by EPR spin-probe technique (2000) (57)
Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries. (2010) (56)
Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD-Matrix Trial. (2017) (56)
Plaque composition in the left main stem mimics the distal but not the proximal tract of the left coronary artery: influence of clinical presentation, length of the left main trunk, lipid profile, and systemic levels of C-reactive protein. (2007) (56)
Prediction of 1-year mortality in patients with acute coronary syndromes undergoing percutaneous coronary intervention: validation of the logistic clinical SYNTAX (Synergy Between Percutaneous Coronary Interventions With Taxus and Cardiac Surgery) score. (2013) (55)
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. (2020) (54)
Serum xanthine oxidase in human liver disease (2001) (54)
Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. (2016) (53)
Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. (2016) (53)
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). (2014) (53)
Genetic determinants of on-clopidogrel high platelet reactivity (2011) (53)
The Impact of Left Ventricular Diastolic Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. (2018) (52)
Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST) study. (2013) (52)
Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE‐TAVI AF trial (2018) (51)
The Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures (2016) (51)
Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. (2021) (50)
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. (2016) (49)
Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation (2017) (49)
Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. (2004) (49)
Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial (2016) (48)
Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era. (2006) (48)
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). (2018) (48)
Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial (2014) (47)
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis (2021) (47)
The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. (2009) (47)
Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients. (2019) (47)
Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. (2015) (47)
Predicting 3-year mortality after percutaneous coronary intervention: updated logistic clinical SYNTAX score based on patient-level data from 7 contemporary stent trials. (2014) (47)
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. (2014) (47)
Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. (2016) (47)
Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program. (2014) (46)
Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study (2019) (46)
Rates and predictors of hospital readmission after transcatheter aortic valve implantation (2017) (46)
Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. (2020) (46)
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study. (2018) (45)
Long‐term outcome in patients with ST segment elevation myocardial infarction and multivessel disease treated with culprit‐only, immediate, or staged multivessel percutaneous revascularization strategies: Insights from the REAL registry (2014) (45)
Short-Term Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Elderly Patients: A Meta-Analysis of Individual Participant Data From 6 Randomized Trials. (2018) (44)
Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. (2019) (44)
One year clinical follow up of paclitaxel eluting stents for acute myocardial infarction compared with sirolimus eluting stents (2005) (44)
Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses. (2019) (43)
Percutaneous therapy of bifurcation lesions with drug‐eluting stent implantation: the Culotte technique revisited (2005) (43)
Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study. (2007) (43)
Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. (2011) (43)
Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial. (2018) (42)
Assisted circulation using the TandemHeart® during very high‐risk PCI of the unprotected left main coronary artery in patients declined for CABG (2009) (42)
Intramyocardial injection of skeletal myoblasts: long-term follow-up with pressure–volume loops (2006) (41)
Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. (2015) (41)
Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials (2010) (40)
Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis (2017) (40)
Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials. (2013) (39)
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? (2014) (39)
Rationale and methods of the integrated biomarker and imaging study (IBIS): combining invasive and non-invasive imaging with biomarkers to detect subclinical atherosclerosis and assess coronary lesion biology (2005) (38)
Migratory activity of circulating progenitor cells and serum SDF-1α predict adverse events in patients with myocardial infarction. (2013) (38)
Pretreatment With P2Y12 Inhibitors in Non–ST-Segment–Elevation Acute Coronary Syndrome Is Clinically Justified (2014) (38)
Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force (2015) (38)
Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. (2015) (38)
Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. (2016) (37)
Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). (2013) (37)
Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: A systematic review and meta‐analysis (2018) (37)
Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for ostial/midshaft lesions in unprotected left main coronary artery from the DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass (2014) (37)
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial. (2019) (36)
One-year clinical outcome after coronary stenting of very small vessels using 2.25 mm sirolimus- and paclitaxel-eluting stents: a comparison between the RESEARCH and T-SEARCH registries. (2005) (36)
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention (2017) (36)
State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives. (2017) (36)
Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices (2000) (36)
Bleeding avoidance strategies in percutaneous coronary intervention (2021) (36)
Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis (2007) (36)
Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry (2018) (35)
Incidence, prognostic impact, and optimal definition of contrast‐induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all‐comer PRODIGY trial (2015) (35)
Factor XIIIA-V34L and Factor XIIIB-H95R Gene Variants: Effects on Survival in Myocardial Infarction Patients (2007) (35)
Stress and tissue Doppler echocardiographic evidence of effectiveness of myoblast transplantation in patients with ischaemic heart failure (2006) (34)
Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: the DEMONSTRATE study. (2014) (34)
Drug-eluting stent implantation for chronic total occlusions: comparison between the Sirolimus- and Paclitaxel-eluting stent. (2005) (34)
Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. (2021) (33)
Revisiting late loss and neointimal volumetric measurements in a drug‐eluting stent trial: Analysis from the SPIRIT FIRST trial (2006) (33)
Impact of vascular access on acute kidney injury after percutaneous coronary intervention. (2016) (33)
Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. (2016) (33)
Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis (2018) (32)
Optimization in Stent Implantation by Manual Thrombus Aspiration in ST-Segment–Elevation Myocardial Infarction: Findings From the EXAMINATION Trial (2014) (32)
Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition. (2021) (32)
Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. (2019) (32)
Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5,433 patients enrolled in contemporary coronary stent trials. (2015) (32)
Use of Impella Recover(R) LP 2.5 left ventricular assist device during high-risk percutaneous coronary interventions; clinical, haemodynamic and biochemical findings. (2006) (31)
Relationship between paraoxonase Q192R gene polymorphism and on‐clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention (2011) (31)
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction (2020) (31)
Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment–Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel: The REDUCE-MVI Trial (2019) (31)
Stents liberadores de fármacos frente a stents convencionales en pacientes diabéticos con infarto agudo de miocardio con elevación del segmento ST: un análisis combinado de los datos de pacientes individuales de 7 ensayos aleatorizados (2009) (31)
Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. (2018) (30)
Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea. (2018) (30)
Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST (2013) (30)
Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial (2021) (30)
Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus? (2015) (30)
Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis. (2015) (29)
Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design (2008) (29)
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. (2014) (29)
Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials. (2011) (29)
Acute kidney injury after percutaneous coronary intervention: Rationale of the AKI‐MATRIX (acute kidney injury‐minimizing adverse hemorrhagic events by TRansradial access site and systemic implementation of angioX) sub‐study (2015) (29)
Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. (2018) (29)
Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. (2016) (29)
Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. (2005) (29)
Impact of stable versus unstable coronary artery disease on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents: a subanalysis of the ARTS II trial. (2007) (28)
Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry. (2016) (28)
The impact of functional vs degenerative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation (2017) (28)
Early angio-guided complete revascularization versus culprit vessel PCI followed by ischemia-guided staged PCI in STEMI patients with multivessel disease. (2011) (28)
Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. (2012) (28)
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. (2021) (28)
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). (2016) (27)
Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. (2016) (27)
Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials (2009) (27)
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes (2014) (27)
Intracardiac echocardiography guidance during percutaneous transluminal septal myocardial ablation in patients with obstructive hypertrophic cardiomyopathy (2005) (27)
Impact of chronic kidney disease on 2‐year clinical outcomes in patients treated with 6‐month or 24‐month DAPT duration: An analysis from the PRODIGY trial (2017) (26)
Patient-tailored antithrombotic therapy following percutaneous coronary intervention (2021) (26)
Transfemoral Approach for Coronary Angiography and Intervention: A Collaboration of International Cardiovascular Societies. (2017) (26)
Defining the Role of Platelet Glycoprotein Receptor Inhibitors in STEMI (2009) (26)
Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. (2020) (26)
Is late luminal loss an accurate predictor of the clinical effectiveness of drug-eluting stents in the coronary arteries? (2006) (25)
Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial (2019) (25)
Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: the sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT). (2009) (25)
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. (2020) (25)
Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? (2018) (25)
A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). (2016) (25)
European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. (2021) (25)
Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients. (2013) (24)
Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. (2018) (24)
Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. (2007) (24)
Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. (2019) (24)
Antithrombotic therapy in TAVI patients: changing concepts. (2015) (24)
ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation (2013) (24)
Rapid exchange ultra-thin microcatheter using fibre-optic sensing technology for measurement of intracoronary fractional flow reserve. (2015) (24)
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial. (2016) (24)
Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy (2007) (23)
Treatment of de novo bifurcation lesions: comparison of Sirolimus- and Paclitaxel-eluting stents. (2005) (23)
Benefit of radial approach in reducing the incidence of acute kidney injury after percutaneous coronary intervention: a meta-analysis of 22,108 patients. (2015) (23)
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium (2020) (22)
Genome‐wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC) (2017) (22)
Methodological considerations and approach to cross‐technique comparisons using in vivo coronary plaque characterization based on intravascular ultrasound radiofrequency data analysis: insights from the Integrated Biomarker and Imaging Study (IBIS) (2005) (22)
The Radial Artery for Percutaneous Coronary Procedures or Surgery? (2018) (22)
Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. (2016) (22)
Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials. (2009) (22)
Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration (2017) (22)
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. (2020) (22)
Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX - RAdiation Dose study (RAD-M (2014) (22)
The SYNTAX score on its way out or … towards artificial intelligence: part I. (2020) (22)
Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. (2017) (21)
Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. (2021) (21)
Stable Angina Pectoris (2014) (21)
Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis. (1999) (21)
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. (2019) (21)
How can we optimize the processes of care for acute coronary syndromes to improve outcomes? (2014) (21)
Short‐versus long‐term Dual Antiplatelet therapy after drug‐eluting stent implantation in women versus men: A sex‐specific patient‐level pooled‐analysis of six randomized trials (2017) (21)
Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice. (2019) (21)
Persistence of neointimal growth 12 months after intervention and occurrence of delayed restenosis in patients with left main coronary artery disease treated with drug-eluting stents. (2006) (21)
Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. (2018) (21)
Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study. (2013) (21)
Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention (2019) (20)
Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation. (2017) (20)
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). (2014) (20)
Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression. (2007) (20)
Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. (2017) (20)
Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials (2015) (20)
Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. (2015) (20)
Everolimus-eluting stent versus bare-metal stent in elderly (≥75 years) versus non-elderly (<75 years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the examination trial. (2015) (20)
Neurohormonal modulation in chronic heart failure (2002) (20)
Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting (2021) (20)
Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. (2018) (19)
Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. (2016) (19)
Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts (2010) (19)
In vivo relationship between compositional and mechanical imaging of coronary arteries. Insights from intravascular ultrasound radiofrequency data analysis. (2006) (19)
Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization (2015) (19)
Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial. (2021) (19)
Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent (2012) (19)
Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement? (2020) (19)
Acute kidney injury after primary angioplasty: effect of different hydration treatments (2014) (18)
Device-Related Thrombus After Left Atrial Appendage Closure (2021) (18)
Management of acute coronary syndromes in older adults. (2021) (18)
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. (2021) (18)
Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies (2017) (18)
Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial. (2007) (18)
Current Use of Intracoronary Imaging in Interventional Practice　- Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. (2018) (18)
Effects of pre‐hospital clopidogrel administration on early and late residual platelet reactivity in ST‐segment elevation myocardial infarction patients undergoing primary intervention (2013) (18)
Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions (2015) (17)
Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. (2012) (17)
Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. (2016) (17)
Effects of percutaneous transluminal septal myocardial ablation for obstructive hypertrophic cardiomyopathy on systolic and diastolic left ventricular function assessed by pressure-volume loops. (2008) (17)
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis. (2017) (17)
Myocardial repair by percutaneous cell transplantation of autologous skeletal myoblast as a stand alone procedure in post myocardial infarction chronic heart failure patients. (2006) (17)
Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. (2019) (17)
Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study (2016) (17)
Developing drugs for use before, during and soon after percutaneous coronary intervention (2016) (17)
Mechanical complications in patients with ST-segment elevation myocardial infarction: A single centre experience (2019) (17)
Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. (2019) (17)
Bivalirudin versus heparin in patients with acute myocardial infarction: A meta‐analysis of randomized trials (2015) (16)
Wytyczne ESC/EACTS dotyczące rewaskularyzacji mięśnia sercowego w 2014 roku (2014) (16)
Comparison of percutaneous coronary intervention (with drug-eluting stents) versus coronary artery bypass grafting in women with severe narrowing of the left main coronary artery (from the Women-Drug-Eluting stent for LefT main coronary Artery disease Registry). (2014) (16)
Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis (2016) (16)
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. (2021) (16)
Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). (2010) (16)
A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis. (2016) (16)
Mortality after Bleeding versus Myocardial Infarction in Coronary Artery Disease: A Systematic Review and Meta-Analysis. (2021) (16)
Duration of Antiplatelet Therapy After Complex Percutaneous Coronary Intervention In Patients at High Bleeding Risk: a MASTER DAPT trial sub-analysis. (2022) (16)
Guía de práctica clínica de la ESC sobre revascularización miocárdica, 2014 (2015) (16)
Prognostic value of serial platelet reactivity measurements on long‐term clinical outcome in patients with ST‐elevation myocardial infarction undergoing primary PCI (2008) (16)
In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. (2013) (16)
Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors (2017) (15)
Randomized, double‐blind comparison of effects of abiciximab bolus only vs. on‐label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting (2010) (15)
Angiotensin II overproduction: enemy of the vessel wall (2002) (15)
High-Dose BoluS TiRofibAn and Sirolimus Eluting STEnt versus Abiciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Study—Protocol Design and Demography of the First 100 Patients (2004) (15)
Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk (2020) (15)
Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial (2020) (15)
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease (2021) (15)
Left ventricular volumes in liver cirrhosis. (2000) (15)
Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey. (2016) (15)
Different clinical models of CD34 + cells mobilization in patients with cardiovascular disease (2010) (15)
Clinical outcomes of Watchman vs. Amplatzer occluders for left atrial appendage closure (WATCH at LAAC). (2020) (15)
Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. (2020) (14)
Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. (2019) (14)
Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation: A Pairwise Meta-Analysis of 6 Trials and 21 457 Patients (2019) (14)
The SYNTAX score on its way out or … towards artificial intelligence: part II. (2020) (14)
Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes (2015) (14)
Triple Antiplatelet Therapy in Acute Coronary Syndromes (2011) (14)
The ESC DAPT Guidelines 2017. (2018) (14)
Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents (2010) (14)
Comparing methods for estimating patient‐specific treatment effects in individual patient data meta‐analysis (2020) (14)
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) (2019) (14)
Five‐Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus‐Eluting Stents Versus Durable Polymer Everolimus‐Eluting Stents (2019) (14)
DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. (2020) (14)
Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION trial. (2013) (13)
Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents? (2009) (13)
Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization (2018) (13)
The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin! (2018) (13)
A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. (2020) (13)
Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents (2016) (13)
The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. (2018) (13)
Duplex Doppler findings in splenic arteriovenous fistula (1998) (13)
Rationale and design of the Hunting for the off‐target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI‐TECH) trial (2017) (13)
Cardiac Nerve Growth Factor Overexpression Induces Bone Marrow–derived Progenitor Cells Mobilization and Homing to the Infarcted Heart (2015) (13)
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. (2020) (13)
Uaktualnione stanowisko ESC dotyczące stosowania podwójnej terapii przeciwpłytkowej w chorobie wieńcowej w 2017 roku, przygotowane we współpracy z EACTS (2017) (12)
Revisiting the incidence and temporal distribution of cardiac and sudden death in patients undergoing elective intervention for unprotected left main coronary artery stenosis in the drug eluting stent era. (2007) (12)
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre‐Specified Analysis of the GLOBAL LEADERS Trial (2021) (12)
Sex‐Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria (2021) (12)
Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study). (2013) (12)
External validity of the “all-comers” design: insights from the BIOSCIENCE trial (2016) (12)
Current know how on the absorb BVS technology: an experts' survey. (2015) (12)
Acute coronary syndromes: an emphasis shift from treatment to prevention; and the enduring challenge of vulnerable plaque detection in the cardiac catheterization laboratory (2007) (12)
Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology (2019) (12)
Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol (2009) (12)
Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk: navigating between limited evidence and clinical concerns (2015) (12)
Antithrombotic Therapy after Percutaneous Coronary Intervention of Bifurcation Lesions. (2020) (12)
[Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation]. (2016) (11)
Design and Rationale of the XIENCE Short DAPT Clinical Program: an Assessment of the Safety of 3-month or 1-month DAPT in Patients at High Bleeding Risk Undergoing PCI with an Everolimus-Eluting Stent. (2020) (11)
Sex‐Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient‐Level Pooled Analysis From 4 Postapproval Studies (2020) (11)
The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up (2018) (11)
Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST‐Segment–Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long‐Term Follow‐Up of the REDUCE‐MVI Trial (2020) (11)
Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The diabetes and drug eluting stent for LeFT main registry (D-DELFT). (2008) (11)
Management of antithrombotic therapy in atrial fibrillation patientspresentingwith acutecoronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart (2014) (11)
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention (2022) (11)
The conundrum of antithrombotic drugs before, during and after primary PCI. (2014) (11)
Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores. (2020) (11)
Clinical relevance of ticagrelor monotherapy following 1‐month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial (2020) (11)
Validation of the updated Logistic Clinical SYNTAX score for all-cause mortality in GLOBAL LEADERS trial. (2019) (11)
The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial (2020) (11)
Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. (2020) (10)
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with ACS: a meta-analysis. (2021) (10)
Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial (2020) (10)
Immune activation in severe heart failure Does etiology play a role (2004) (10)
Questions and answers on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†. (2020) (10)
Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials (2022) (10)
Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function. (2018) (10)
Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS) (2021) (10)
Computed tomography detection and quantification of left atrial appendage residual patency as collateral finding after percutaneous closure. (2018) (10)
Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials (2020) (10)
Anatomic Characteristics and Clinical Implications of Angiographic Coronary Thrombus: Insights From a Patient-Level Pooled Analysis of SYNTAX, RESOLUTE, and LEADERS Trials (2015) (10)
Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial. (2018) (10)
What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. (2010) (9)
Comparative frequency and prognostic impact of myocardial injury in hospitalized patients with COVID-19 and Influenza (2021) (9)
Safety evaluation of tirofiban (2010) (9)
TRADEOFF BETWEEN MYOCARDIAL INFARCTION VERSUS BLEEDING TYPES ON MORTALITY AFTER ACUTE CORONARY SYNDROME: LESSONS FROM THE THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME (TRACER) RANDOMIZED TRIAL (2016) (9)
Long‐term outcome after percutaneous coronary intervention in patients with essential thrombocythemia (2009) (9)
Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy. (2014) (9)
Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. (2021) (9)
Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle. (2017) (9)
Use of PRECISE-DAPT Score and Admission Platelet Count to Predict Mortality Risk in Patients With Acute Coronary Syndrome (2019) (9)
Impact of left ventricular function on clinical outcomes among patients with coronary artery disease (2019) (9)
CHOICES IN ANTITHROMBOTIC MANAGEMENT FOR PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. QUESTIONS (AND ANSWERS) IN CHRONOLOGICAL SEQUENCE. (2020) (9)
Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. (2017) (9)
Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation. (2018) (9)
Percutaneous coronary intervention or coronary artery bypass graft for unprotected left main coronary artery disease: the endless debate. (2008) (9)
Latest clinical data on testing for high on-treatment platelet reactivity. (2011) (9)
Radial versus femoral access for cardiac catheterisation – Authors' reply (2015) (9)
Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial. (2019) (9)
Saturday, 25 August 2012 (2012) (9)
Determinants of radiation dose during right transradial access: Insights from the RAD‐MATRIX study (2018) (9)
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials. (2022) (8)
Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis (2020) (8)
Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome. (2020) (8)
Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study (2016) (8)
Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. (2020) (8)
Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial). (2018) (8)
Impact of Ticagrelor Monotherapy on Two-Year Clinical Outcomes in Patients with Long Stenting: A Post Hoc Analysis of the Global Leaders Trial. (2020) (8)
Rationale and study design of the RESERVOIR trial: A randomized trial comparing reservoir‐based polymer‐free amphilimus‐eluting stents versus everolimus‐eluting stents with durable polymer in patients with diabetes mellitus (2015) (8)
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. (2018) (8)
Neurohormones, Cytokines and Programmed Cell Death in Heart Failure: A New Paradigm for the Remodeling Heart (2001) (7)
Wytyczne ESC dotyczace postepowania w ostrych zespolach wiencowych bez przetrwalego uniesienia odcinka ST w 2015 roku. (2015) (7)
Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials. (2012) (7)
Peri-procedural myocardial infarction and troponism: a quick journey through the land of confusion (2012) (7)
Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. (2008) (7)
Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: The PERSEUS Randomized Trial. (2020) (7)
Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial (2020) (7)
Will LEADERS-FREE change my practice? A randomised double-blind comparison of the BioFreedom™ drug-coated stent vs. the Gazelle™ bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. (2016) (7)
Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention? (2019) (7)
Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease (2018) (7)
Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. (2019) (7)
Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial. (2016) (7)
2017 European Society of Cardiology (ESC) focused update on dual antiplatelet therapy in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) (2018) (7)
Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities. (2015) (7)
A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. (2019) (7)
Abciximab: a reappraisal of its use in coronary care (2008) (7)
Carotid stent cell design: lack of benefit or lack of evidence? (2008) (7)
Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention (2020) (7)
Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. (2021) (7)
Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study (2016) (7)
Effectiveness of Pretreatment With Dual Oral Antiplatelet Therapy. (2015) (7)
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale (2020) (7)
Cost‐effectiveness of percutaneous coronary intervention with cobalt‐chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta‐analysis of randomized trials (2016) (7)
Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. (2020) (6)
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events (2020) (6)
Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. (2020) (6)
Prognostic impact of invasive haemodynamic measurements in combination with clinical and echocardiographic characteristics on two-year clinical outcomes of patients undergoing transcatheter aortic valve implantation. (2017) (6)
Myocardial ischaemia: new evidence for angiotensin-converting enzyme inhibition (2003) (6)
Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. (2015) (6)
Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. (2019) (6)
Distal vs Conventional Radial Access for Coronary Angiography and/or Intervention: A Meta-Analysis of Randomized Trials. (2022) (6)
Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial. (2017) (6)
Optical coherence tomography appraisal of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing intraprocedural versus post-stenting prolonged bivalirudin infusion. Rationale and design of the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Acc (2015) (6)
Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. (2022) (6)
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. (2019) (6)
Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: insights from the EXAMINATION trial. (2013) (6)
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy. (2010) (6)
Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†. (2016) (6)
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions. (2023) (6)
Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. (2018) (6)
Impact of Echocardiographic Guidance on Safety and Efficacy of Left Atrial Appendage Closure: An Observational Study. (2021) (6)
Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease (2017) (6)
Paclitaxel eluting stents for the treatment of angiographically non‐significant atherosclerotic lesions (2005) (6)
Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization (2020) (6)
Validation and Additive Predictive Value of the Academic Research Consortium—High Bleeding Risk Criteria in Older Adults (2020) (5)
Abstract 16065: Sex-Specific Benefits of Sirolimus Eluting Stent on Long Term Outcomes in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Insights From the MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abcixim (2011) (5)
Current-era biovascular scaffolds seen by experts: An experience-based survey. (2015) (5)
Sunday, 26 August 2012 (2012) (5)
A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial (2008) (5)
Coronary artery disease Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction : a collaborative meta-analysis of randomized trials (2016) (5)
Dual antiplatelet therapy duration: what are the drivers? (2011) (5)
5232Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 antagonist, in acute myocardial infarction: a randomised open-label phase 2 study (2019) (5)
Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after myocardial infarction (2008) (5)
Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. (2019) (5)
New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios (2005) (5)
Cardiovascular risk profile of patients included in stent trials; a pooled analysis of individual patient data from randomised clinical trials: insights from 33 prospective stent trials in Europe. (2011) (5)
Femoral Access With or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome. (2019) (5)
Long‐term prognostic value of risk scores after drug‐eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR‐LEFT‐MAIN and ISAR‐LEFT‐MAIN 2 randomized clinical trials (2017) (5)
Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests (2013) (5)
Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial (2018) (5)
Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. (2021) (5)
Impact of established cardiovascular disease on outcomes in the randomized global leaders trial (2019) (5)
Predicting 2‐year all‐cause mortality after contemporary PCI: Updating the logistic clinical SYNTAX score (2021) (5)
Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy (2020) (5)
IMPACT OF CLOPIDOGREL ON-TREATMENT PLATELET REACTIVITY ON STENT THROMBOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION: RESULTS FROM A COLLABORATIVE META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA (2011) (5)
Application of the MADS classification system in a “mega mammoth” stent trial: Feasibility and preliminary clinical implications (2018) (5)
Regional variation in patients and outcomes in the GLOBAL LEADERS trial. (2020) (5)
Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. (2020) (4)
ESC Guidelines on the management of acute myocardial infarction with persistent ST-segment elevation (2012) (4)
Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure (2021) (4)
Cardioprotection with ACE inhibitors : non-angiotensin II-related mechanisms (2000) (4)
Response by Costa et al to Letter Regarding Article, "The Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures". (2016) (4)
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk. (2022) (4)
Letters Regarding Article by Patti et al, “Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) S (2005) (4)
Ischaemic and bleeding risk in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: is it time to REACT? (2021) (4)
Randomized Tailoring Treatment With Tirofiban in Clopidogrel , or Both Agents Undergoing Elective Coronary Intervention : Results From Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin (2009) (4)
Drug-eluting stents in primary PCI. (2006) (4)
Quantification of scientific output in cardiovascular medicine: a perspective based on global data. (2013) (4)
From secondary to tertiary mitral regurgitation: the paradigm shifts, but uncertainties remain. (2021) (4)
A new iteration for the single-access large-bore technique during Impella supported complex and high-risk coronary intervention: a case report (2021) (4)
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial (2022) (4)
Dual Antiplatelet Therapy After Drug-eluting Stent Implantation. (2015) (4)
Radiation Exposure and Vascular Access€in€Acute Coronary Syndromes (4)
Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial (2020) (4)
Comparison of Bivalirudin Versus Heparin(s) During Percutaneous Coronary Interventions in Patients Receiving Prasugrel: A Propensity‐Matched Study (2014) (4)
Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting (2010) (4)
Temporal and Genotype-Driven Variation of Factor VII Levels in Patients With Acute Myocardial Infarction (2009) (4)
TCT-14 Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 12-month follow-up- BIOSOLVE-II and BIOSOLVE-III (2017) (4)
Influence of operator experience and PCI volume on transfemoral access techniques: A collaboration of international cardiovascular societies. (2017) (4)
Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. (2019) (4)
A prospective, first-in-human use of the NeVa mechanical thrombectomy device for patients with acute coronary syndromes. (2022) (4)
Deferred angioplasty and stenting in primary percutaneous coronary intervention: one step back, two steps forward? (2013) (4)
The impact of the COVID-19 pandemic upon patients, staff, and on the future practices of percutaneous coronary intervention (2020) (4)
A call for action in bleeding prevention (2019) (3)
Prognostic Relevance of Left Ventricular Myocardial Performance After Transcatheter Aortic Valve Replacement (2019) (3)
Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome (2010) (3)
Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help (2020) (3)
Appraising the safety and efficacy profile of left atrial appendage closure in 2016 and the future clinical perspectives. Results of the EAPCI LAAC survey. (2016) (3)
Comparative Outcomes After Percutaneous Coronary Intervention in Unconscious and Conscious Patients With Out-of-Hospital Cardiac Arrest. (2022) (3)
TCT-747 Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis (2012) (3)
Drug‐Eluting or Bare‐Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization (2021) (3)
COMBINED ANATOMICAL AND CLINICAL FACTORS FOR THE RISK STRATIFICATION OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: THE LOGISTIC CLINICAL SYNTAX SCORE (2012) (3)
Distal Transradial Access for Coronary Procedures (2021) (3)
Obstructive sleep apnoea syndrome and endothelial function: potential impact of different treatment strategies—meta-analysis of prospective studies (2019) (3)
Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial (2019) (3)
Correlates and Impact of Coronary Artery Calci ﬁ cations in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (3)
Keeping a high standard in quantitative analyses, meta-analyses, and systematic reviews. (2007) (3)
Radial versus femoral access in ACS patients undergoing complex PCI is associated with consistent bleeding benefit and no excess of risks. (2022) (3)
Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. (2021) (3)
Cardiovascular mortality and morbidity in patients undergoing percutaneous coronary intervention after out-of-hospital cardiac arrest: a systematic review and meta-analysis. (2020) (3)
Deciding on the Duration of Dual Antiplatelet Therapy-When the Choice Between 2 Evils Is Still Evil. (2017) (3)
P2812Ischemic efficacy and bleeding safety of ticagrelor monotherapy in patients with multivessel percutaneous coronary intervention: insights from the Global Leaders trial (2019) (3)
Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. (2021) (3)
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). (2019) (3)
Beyond crossing a chronic total occlusionAre the drug-eluting stents the solution for this old problem? (2005) (3)
Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban (2010) (3)
Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. (2021) (3)
Development and validation of a risk model for long‐term mortality after percutaneous coronary intervention: The IDEA‐BIO Study (2018) (3)
Bivalirudin in Current Practice: Melius Abundare Quam Deficere? (2016) (3)
Digital Gangrene Following Transradial Coronary Angiogram. (2016) (3)
OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting Prolonged Bivalirudin Infusion: The MATRIX OCT Study. (2019) (3)
DAPT Duration After Drug-Eluting Stent Implantation: No News Is Good News. (2017) (3)
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. (2022) (3)
Usefulness of updated logistic clinical SYNTAX score based on MI‐SYNTAX score in patients with ST‐elevation myocardial infarction (2020) (3)
ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome (2014) (3)
Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial. (2019) (3)
ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome (2014) (3)
Efficacy of Radial Versus Femoral Access in the Acute Coronary Syndrome: Is It the Operator or the Operation That Matters? (2016) (3)
A DOUBLE BLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY OF BINDARIT IN PREVENTING CORONARY STENT RESTENOSIS (2012) (3)
Assessment of residual thrombus burden in patients with ST‐segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study (2019) (3)
Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry (2022) (3)
Chronic Thrombocytopenia and Percutaneous Coronary Intervention: The Virtue of Prudence. (2018) (3)
Factor XIIIA-V 34 L and Factor XIIIB-H 95 R Gene Variants : Effects on Survival in Myocardial Infarction Patients (2007) (2)
Abstract 3071: Meta-Analysis of High-Dose Single-Bolus Tirofiban versus Abciximab in Patients Undergoing Percutaneous Coronary Interventions (2006) (2)
ETHNIC DIFFERENCES IN ISCHEMIA/BLEEDING RISK TRADE OFF DURING ANTIPLATELET THERAPY POST- DRUG-ELUTING STENT IMPLANTATION: INDIVIDUAL PATIENT LEVEL META-ANALYSIS FROM SEVEN RANDOMIZED CLINICAL TRIALS (2018) (2)
Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines. (2019) (2)
Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. (2019) (2)
“Tailored” antiplatelet bridging therapy with cangrelor: moving toward personalized medicine (2021) (2)
Discharge Location and Outcomes after Transcatheter Aortic Valve Implantation. (2020) (2)
Five-year outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with acute coronary syndrome: A subgroup analysis of the BIOSCIENCE trial. (2021) (2)
Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies (2021) (2)
[ANMCO/SICI-GISE document on antiplatelet therapy in patients with acute coronary syndrome]. (2013) (2)
The Use of Radial Access for Cardiac Catheterization: Slowly, But Yet it Moves. (2019) (2)
'Ten Commandments' of the 2017 ESC DAPT focused update Guidelines. (2018) (2)
Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization (2016) (2)
Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study. (2022) (2)
Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries (2022) (2)
Activated Clotting Time During Unfractionated Heparin-Supported Coronary Intervention: Is Access Site the New Piece of the Puzzle? (2018) (2)
Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS). (2020) (2)
Abstract 18805: Vorapaxar, A Platelet Thrombin-Receptor Antagonist, in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from the TRACER Trial (2012) (2)
[Current options to manage clopidogrel poor responsiveness]. (2010) (2)
Two‐year clinical outcomes after successful transcatheter aortic valve implantation with balloon‐expandable versus self‐expanding valves: A subanalysis of the GALILEO trial (2022) (2)
Time for science to catch up with clinical practice? (2015) (2)
Large-Bore Radial Access for Complex PCI: A Flash of COLOR With Some Shades of Grey. (2021) (2)
Radial versus femoral approach in STEMI: what do we know so far? (2016) (2)
Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. (2019) (2)
CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS : Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial (2013) (2)
Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives. (2006) (2)
Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention (2021) (2)
Posters Presentations (2022) (2)
Ticagrelor versus Prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. (2021) (2)
The heart of coronary arteries. (2007) (2)
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. (2021) (2)
[Late-appearing cholestatic icterus after a month of treatment with ticlopidine]. (2001) (2)
Shifting the focus to recurrences: so good we can afford it or too bad we cannot avoid it? (2014) (2)
Effect of Chronic Kidney Disease in WomenUndergoing Percutaneous CoronaryIntervention With Drug-ElutingStents (2)
Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus‐eluting stents (2020) (2)
Clinical implications of the PROTECT-TIMI-30 trial. (2007) (2)
Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial (2022) (2)
This appendix has been provided by the authors to give readers additional information about their work. (2015) (2)
Lugar de acceso y tipo de anticoagulante en pacientes con síndrome coronario agudo en clase Killip avanzada o con parada cardiaca extrahospitalaria (2020) (2)
Subcutaneous RUC-4 for acute myocardial infarction: a new treatment on the horizon for pre-hospital care? (2021) (1)
Radiation Exposure and Vascular Access in Acute Coronary Syndromes: A Randomised Multicentre Trial (1)
Bivalirudin in Acute Coronary Syndromes. Authors reply. (2016) (1)
Will PIONEER AF-PCI change my practice? (2017) (1)
LONG-TERM TICAGRELOR MONOTHERAPY IN ELDERLY PATIENTS UNDERGOING PCI IN THE GLOBAL LEADERS STUDY (2019) (1)
[Highlights from the 2015 ESC NSTE-ACS Guidelines]. (2016) (1)
Use of granulocyte colony-stimulating factor during acute MI: Fact or fiction? (2008) (1)
Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial / Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry A Multicenter Registry Evaluating Percutaneous Coronary Intervention Versus Coronary Artery Bypas (1)
Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry. (2022) (1)
Sex-differences in outcomes after PCI or CABG for left main disease: from the DELTA registries (2020) (1)
TCT-213 Efficacy and Safety of Long- Versus Short-Term Dual Antiplatelet Therapy Following Complex Percutaneous Coronary Intervention with Drug-Eluting Stents: A Collaborative Patient-Level Pooled Analysis of Randomized Controlled Trials. (2016) (1)
LONG-TERM SAFETY OF TICAGRELOR MONOTHERAPY IN PATIENTS UNDERGOING PCI FOR STABLE CORONARY ARTERY DISEASE IN THE GLOBAL LEADERS STUDY: IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2019) (1)
TCT-645 Optical coherence tomography findings in bioresorbable scaffold thrombosis (2014) (1)
From chaotic to coordinated clinical research: the case of acetylcysteine. (2006) (1)
TCT-539 Clinical outcomes in high bleeding risk patients undergoing complex PCI with the Xience everolimus eluting stent: a patient-level pooled analysis from four Xience post-approval trials (2018) (1)
Acute coronary syndromes : from treatment to prevention . The enduring challenge of vulnerable plaque detection in the cardiac catheterization laboratory (2006) (1)
Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial. (2023) (1)
Association among myocardial injury and mortality in Influenza: A prospective cohort study. (2022) (1)
Additional value of CMR feature tracking parameters for the evaluation of the risk of complex ventricular arrhythmias and sudden cardiac death in patients with Mitral Valve Prolapse (2022) (1)
TCT-453 Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. (2016) (1)
Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) st (2005) (1)
Patients With Atrial Fibrillation and PCI or ACS: Does Predicted Risk Matter? (2022) (1)
Operators' experience with radial access for cardiac catheterization in patients with acute coronary syndromes. (2018) (1)
DETERMINATION OF THE URINARY NEUTROPHIL GELATINASE–ASSOCIATED LIPOCALIN AS AN EARLY MARKER OF CONTRAST INDUCED ACUTE KIDNEY INJURY AFTER CORONARY CATHETERIZATION (2013) (1)
Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial (2022) (1)
Novel directions for the management of dual antiplatelet therapy in patients with coronary artery disease (2019) (1)
A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. (2008) (1)
VARIABILITY IN TRANSFEMORAL ACCESS FOR CORONARY ANGIOGRAPHY AND INTERVENTIONS: RESULTS FROM AN INTERNATIONAL SURVEY (2017) (1)
IMP 1211 Splanchnic and systemic hemodynamic response to meal in cirrhotics with different bleeding risk (1997) (1)
Individual Patient Data Meta-analysis of Drug-eluting Versus Bare-metal Stents for Percutaneous Coronary Intervention in Chronic Versus Acute Coronary Syndromes. (2022) (1)
Acute Coronary Occlusion in Patients With Non-ST-Segment Elevation Out-of-Hospital Cardiac Arrest. (2023) (1)
Comparison of Angioplasty With Infusion ofTirofibanorAbciximabandWithImplantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction (2017) (1)
Long-term dual antiplatelet therapy and concomitant optimal medical therapy following percutaneous coronary intervention. (2017) (1)
Response by Valgimigli and Gargiulo to Letter Regarding Article, "A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?" (2017) (1)
Looking back into the future: desirudin in acute coronary syndromes and coronary stenting. (2011) (1)
P2811Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: insights from the Global Leaders trial (2019) (1)
TCT-481 Comparison of newer generation drug-eluting stents with bare metal stents in patients with acute ST-segment elevation myocardial infarction: A pooled analysis of EXAMINATION and COMFORTABLE AMI trials (2012) (1)
Detection and treatment of vulnerable plaque (2004) (1)
Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment-elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. (2021) (1)
Impact of optical coherence tomography findings on clinical outcomes in ST-segment elevation myocardial infarction patients: a MATRIX (Minimizing Adverse Hemorrhagic Events by Trans-radial Access Site and angioX) OCT sub-study (2020) (1)
TCT-288 Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Intervention: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaborative Patient-Level Pooled Analysis. (2016) (1)
First clinical pilot study with intravascular polarization sensitive optical coherence tomography (Conference Presentation) (2016) (1)
Meeting the Unmet - The Cre8 Polymer-free Drug-eluting Stents Technology: Proceedings of a satellite symposium held at EuroPCR on May 20th - 23rd 2014 in Paris. (2014) (1)
TCT-566 Cost-Effectiveness Of The Xience™ Cobalt Chromium Everolimus Eluting Stent Compared With Bare Metal Stents: A United States Payer Perspective (2015) (1)
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy. (2022) (1)
Left atrial adaptation in ischemic heart disease: insights from a cardiovascular magnetic resonance study (2022) (1)
How should I treat this unusual anterolateral ST-elevation myocardial infarction with recurrent ventricular fibrillation and cardiac arrest? (2016) (1)
Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study. (2012) (1)
External validation of the GRACE risk score 2.0 in the contemporary all‐comers GLOBAL LEADERS trial (2021) (1)
Not only lungs: COVID-19 hits platelets as well. (2022) (1)
How would I treat (2016) (1)
Reply (2019) (1)
Plaque sealing: are the benefits outweighing the risks? (2007) (1)
Abbreviated dual antiplatelet therapy after PCI in patients at high bleeding risk: a collaborative meta-analysis of randomized trials (2022) (1)
ong-Term Outcomes After Stenting f Bifurcation Lesions With the “ Crush ” Technique redictors of an Adverse Outcome (2006) (1)
P3179Exploring the value of the PRECISE-DAPT score after complex percutaneous coronary intervention to inform dual antiplatelet therapy duration decision-making (2018) (1)
Antithrombotic treatment strategies after PCI – Authors' reply (2020) (0)
TCT-170 Impact of rate of recruitment on all-cause mortality: Insights from the GLOBAL LEADERS all-comers trial (2018) (0)
Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial (2022) (0)
[The FATA study]. (2009) (0)
Treatment of non-ST elevation acute coronary syndromes (2018) (0)
The benefit and harm of treating STEMI: Between ischemia, bleeding, and reperfusion injury (2020) (0)
P1968Five-year outcomes in patients with diabetes mellitus treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents (2019) (0)
OP-203 EFFICACY AND SAFETY OF PLATELET FUNCTION-GUIDED ANTIPLATELET THERAPY: SYSTEMATIC REVIEW AND META-ANALYSIS (2012) (0)
BleedingandstentthrombosisonP 2 Y 12-inhibitors : collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention (2015) (0)
PERCUTANEOUS CORONARY INTERVENTION : A CONTEMPORARY ASSESSMENT (2008) (0)
TCT-642 PARIS Risk Score Stratified Analysis of Clinical Outcomes Among Elderly Patients (Aged > 75 Years) Treated With 23-Month Ticagrelor Monotherapy Following 1-Month DAPT After PCI in the GLOBAL LEADERS Trial (2019) (0)
TCT-475 Effect of Stent Diameter in Women Undergoing Percutaneous Coronary Intervention with Early- and New-Generation Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. (2016) (0)
P1952Value of GRACE risk score in risk stratification in acute coronary syndrome patients undergoing PCI in the Global Leaders study (2019) (0)
Clinical dilemmas on managing antiplatelet therapies after percutaneous coronary intervention: benefits versus risks (2011) (0)
Association of Serum PCSK9 with Near-Infrared Spectroscopy Derived Lipid Core Burden Index and Long-Term Cardiac Outcome (2019) (0)
Short dual antiplatelet therapy duration in high bleeding risk patients undergoing PCI for non-ST-elevation acute coronary syndrome (2022) (0)
Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry (2018) (0)
Acute Coronary Syndromes PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRA·CER TRIAL (2012) (0)
Antithrombotic Therapy After Left Atrial Appendage Occlusion (2022) (0)
[Bioequivalence and excipients: the case of tirofiban. A warning from the Italian Society of Interventional Cardiology (SICI-GISE)]. (2017) (0)
Antithrombotic therapy in patients with established atherosclerotic coronary disease (2023) (0)
3-Year Clinical Data Continue to Show Superiority of Sirolimus-Eluting versus Bare Metal Stents in STEMI Patients (2007) (0)
Tirofiban Significantly Reduces Myocardial Damage after PCI Compared with Standard Antiplatelet Therapy (2008) (0)
Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: The ESC-EORP CICD-LT registry. (2022) (0)
Effects of distal radial access vs conventional radial access in patients undergoing coronary angiography and/or intervention: a meta-analysis of randomised trials (2022) (0)
Effects of Body Mass Index on ClinicalOutcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (2017) (0)
Normal 3DE Anatomy of Atrial Septum: Image Display and Anatomical Specimen Correlations (2021) (0)
ADVANCE praise. Authors' reply (2005) (0)
Effect of thienopyridines discontinuation on mortality or MI after SES versus BMS implantation in STEMI (2007) (0)
No free lunch—the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI (2020) (0)
CORE LABORATORY ASSESSMENT OF NON-FATAL Q-WAVE MYOCARDIAL INFARCTION IN THE GLOBAL LEADERS TRIAL: METHODS AND FINDINGS (2019) (0)
Impact of individual stroke risk on outcome after Amplatzer left atrial appendage closure in patients with atrial fibrillation (2020) (0)
How to overcome aspirin and P 2 Y 12 blocker resistance in secondary prevention in high-risk patients ? - (2011) (0)
Impact of myocardial injury on mortality and adverse events in hospitalized patients with influenza: a prospective cohort study (2022) (0)
TCT-844 Long term risk for major bleeding and ischemic events after PCI with implantation of everolimus-eluting stents: A Pooled-level Analysis of 8,020 Patients (2018) (0)
PREDICTION OF ONE-YEAR MORTALITY IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PCI FROM THE ACUITY (ACUTE CATHETERIZATION AND URGENT INTERVENTION TRIAGE STRATEGY) TRIAL VALIDATION OF THE LOGISTIC CLINICAL SYNTAX SCORE (2013) (0)
The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events? (2020) (0)
Ticagrelor monotherapy beyond 1 month versus standard dual antiplatelet therapy after drug-eluting coronary stenting: a pre-specified per-protocol analysis of the GLOBAL LEADERS trial (2020) (0)
P4891Procedural safety and long-term clinical outcome of left atrial appendage closure according to predefined stroke risk (2017) (0)
The MATRIX trial – Author's reply (2019) (0)
Tissue characterization of small hepatic tumors. Quantitative doppler spectral analysis vs. power doppler flow imaging (1998) (0)
Posters display III clinical outcome and PET (2005) (0)
Reply: Distal Transradial Access in Acute Coronary SyndromesShould We Give the First Try? (2023) (0)
Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease (2017) (0)
TCT-544 Influence of Ischemic and Bleeding Risk Factors on Diabetic Patients Undergoing Percutaneous Coronary Intervention: From the Xience Pooled Registry (2019) (0)
De-escalation in intensity or duration of dual antiplatelet therapy in patients with coronary artery disease: More than alternative treatment options. (2023) (0)
TCT-281 Prognostic Relevance of Left Ventricular Myocardial Performance Following Transcatheter Aortic Valve Replacement (2017) (0)
of confusion land troponism: a quick journey through the Peri-procedural myocardial infarction and (2013) (0)
TCT-636 Impact of Diabetes on the Outcomes in Patients Undergoing Contemporary Percutaneous Coronary Intervention: Analysis From the GLOBAL LEADERS Study (2019) (0)
5-year outcomes in patients with acute coronary syndrome treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents (2020) (0)
Real-world application of currently available decision models for dual antiplatelet therapy duration in acute coronary syndrome (2018) (0)
Interventional Cardiology Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting A Randomized Multicenter Trial (2015) (0)
TCT-256 A Novel Thermoconvection-Equipped Microcatheter (PhysioCath) for Coronary Blood Velocity and Pressure Measurement: Preliminary Experience (2021) (0)
EFFECT OF ALIROCUMAB ON FIRST AND TOTAL REVASCULARIZATIONS IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME IN THE ODYSSEY OUTCOMES TRIAL (2020) (0)
PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE IN HYPERTENSIVE PATIENTS: P1.45 (2000) (0)
Competing risks in the duration of dual antiplatelet therapy—the case for shorter treatment (2021) (0)
Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens (2022) (0)
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of glassy and twilight. (2023) (0)
PCV115 TIROFIBAN IS MORE COST-EFFICIENT THAN ABCIXIMAB IN ACHIEVING ST-SEGMENT RESOLUTION FOLLOWING ACUTE MYOCARDIAL INFARCTION (2009) (0)
ASSOCIATION BETWEEN DURATION OF DUAL ANTIPLATELET THERAPY AND ANGIOGRAPHIC MULTI-VESSEL DISEASE ON OUTCOMES IN PATIENTS TREATED WITH NEWER-GENERATION DRUG-ELUTING STENTS (2017) (0)
MATRIX: Comparison of Transradial and Transfemoral Access and Bivalirudin to Unfractionated Heparin (2015) (0)
IC4 ECONOMIC ANALYSIS OF THE STRATEGY STUDY: TIROFIBAN AND DRUG ELUTING STENTS VERSUS ABCIXIMAB AND BARE METAL STENTS (2005) (0)
Bivalirudina frente a heparina no fraccionada en síndromes coronarios agudos: ¿hay un vencedor? (2016) (0)
Multimodality imaging in the evaluation of left ventricle myocardial deformation determined by edema and scar in acute myocarditis (2022) (0)
INTERVENTIONAL CARDIOLOGY AND SURGERY One year clinical follow up of paclitaxel eluting stents for acute myocardial infarction compared with sirolimus eluting stents (2005) (0)
TCT-397 Edoxaban versus Standard of Care and their Effects on Clinical Outcomes in Patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation – Rationale and Design of the ENVISAGE-TAVI AF Trial (2017) (0)
The PRODIGY Trial - More Information about DAPT after DES Implantation (2011) (0)
TCT-399 Long-Term Cardiovascular Outcomes According to the Antiplatelet Agent Discontinued After Coronary Stenting: Insights From 4 Xience V Post-Approval Studies (2019) (0)
TCT-567 Long-Term Outcomes With an Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent Versus a Cobalt-Chromium Everolimus-Eluting Stent in Single De Novo Coronary Lesions: Four-Year Results of the TARGET I Randomized Controlled Trial (2015) (0)
Tirofiban Noninferior to Abciximab: SES Show Sustained Efficacy in Reducing TVR (2010) (0)
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease: 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Association for Acute CardioVascular Care (ACVC) and European Association of Pr (2023) (0)
P5604Impact of body mass index on outcomes after everolimus-eluting stents versus bare metal stents implantation in patients with ST-segment elevation myocardial infarction: insights the EXAMINATION trial (2017) (0)
Trans-radial coronary approach in patients with ST-segment elevation myocardial infarction: state of the art and future perspectives Acceso coronario transradial en pacientes con infarto de miocardio con elevación del segmento ST: estado del arte y perspectivas futuras (2012) (0)
TCT-419 Long-term clinical outcomes of patients presenting with in-stent restenosis after drug-eluting stent implantation for unprotected left main coronary artery. A pooled analysis of the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 randomized trials (2017) (0)
PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL (2012) (0)
Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy (2020) (0)
Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome. (2023) (0)
351 MULTIPLE PHARMACODYNAMIC ASSESSMENTS OF CANGRELOR EFFECTS IN ELECTIVE COMPLEX PCI: DATA FROM PHARMACODYNAMIC EFFECTS OF CANGRELOR IN PATIENTS WITH ACUTE OR CHRONIC CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION REGISTRY (2022) (0)
IMPACT OF GENDER IN HIGH BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH XIENCE EVEROLIMUS ELUTING STENT: A PATIENT-LEVEL POOLED ANALYSIS FROM FOUR XIENCE POST-APPROVAL TRIALS (2019) (0)
Tirofiban Plus Sirolimus-Eluting Stent vs Abciximab Plus Bare-MetalStent—Reply (2005) (0)
TCT-404 Benefit and Risks of Aspirin on Top of Ticagrelor in Acute Coronary Syndromes: Insights From the Randomized GLOBAL LEADERS Trial (2019) (0)
TCT-345 Optical coherence tomography appraisal of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion. The MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study (2018) (0)
PROGNOSTIC IMPLICATIONS OF SEVERE LESION CALCIFICATION IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (2014) (0)
TCT-112 Patient-oriented clinical outcomes and net adverse cardiovascular event in the Global Leaders trial (2018) (0)
P6411Dyspnea in ticagrelor treated patients in the all-comer randomized GLOBAL LEADERS study and its association with clinical outcomes (2019) (0)
ARE “NEW GENERATION” DES SUPERIOR TO “OLD GENERATION” DES IN REDUCING ADVERSE CLINICAL OUTCOMES AT LONG–TERM FOLLOW–UP: INSIGHTS FROM REAL (REGISTRO REGIONALE ANGIOPLASTICHE DELL'EMILIA–ROMAGNA) MULTICENTER REGISTRY (2013) (0)
Role for substance p based nociceptive signaling in progenitor cell activation and angiogenesis during ischemia in mice (2018) (0)
Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification (2022) (0)
TCT-118 The impact of bifurcation stenting techniques on the clinical events: the stratified analysis of 2,510 bifurcated lesions according to MADS classification in the Global LEADERS trial (2018) (0)
ONE- VERSUS THREE-MONTH DAPT IN OLDER PATIENTS AT HIGH BLEEDING RISK UNDERGOING PCI: INSIGHTS FROM THE XIENCE SHORT DAPT GLOBAL PROGRAM (2023) (0)
IMPACT OF CLINICAL PRESENTATION ON ISCHEMIC AND BLEEDING OUTCOMES IN PATIENTS RECEIVING 6 OR 24 MONTH DURATION OF DUAL ANTIPLATELET THERAPY AFTER STENT IMPLANTATION: A PRE-SPECIFIED ANALYSIS FROM THE (PROLONGING DUAL ANTIPLATELET TREATMENT AFTER GRADING STENT-INDUCED INTIMAL HYPERPLASIA) PRODIGY TRI (2015) (0)
Reply (2018) (0)
Appearance and spontaneous regression of a urinoma in the absence of hydronephrosis during acute obstructive renal disease (1998) (0)
Stent and Dual Antiplatelet Therapy Duration Comparisons in the Setting of a Multicenter Randomized Controlled Trial: Can the Operator Experience Affect the Study Results? (2017) (0)
AMI on the move. (2011) (0)
ONE-YEAR OUTCOMES AFTER TIROFIBAN VERSUS ABCIXIMAB INFUSION IN 745 PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PRIMARY INTERVENTION: INSIGHTS FROM THE MLTISTRATEGY TRIAL (2010) (0)
The Effects of Cangrelor on Platelet Aggregation in STEMI Patients (2022) (0)
CRT-600.1 Reproducibility of an Artificial Intelligence Optical Coherence Tomography Software for Tissue Characterization: Implications for the Design of Longitudinal Studies (2023) (0)
TCT-242 Impact of gender on clinical outcome of everolimus-eluting stent versus bare-metal stent in patients with ST-elevation myocardial infarction. (2013) (0)
[Markers of coronary damage. From diagnosis to prognosis]. (2005) (0)
Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome (2022) (0)
TCT-787 High-Sensitive Cardiac Troponin Predicts 2-years Mortality in Patients with Coronary Artery Disease- subanalysis of the GLOBAL LEADERS trial (2018) (0)
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6-month or 24-month DAPT duration : insights from the PRODIGY trial (2016) (0)
2213Impact of BMI on clinical outcomes in all-comers patients with coronary artery disease undergoing PCI: insights from the Global Leaders study (2019) (0)
Right-ventricular involvement in acute myocarditis assessed by cardiac magnetic resonance feature tracking (2022) (0)
Complete myocardial revascularization : between myth and reality. Authors' reply (2005) (0)
Direct comparisons of sirolimus-eluting and paclitaxel-eluting stents are needed. Commentary. (2005) (0)
TCT-222 Clinical Outcomes of Dual Antiplatelet Therapy after Coronary Stenting in Patients with Chronic Kidney Disease: Patient-level Meta-analysis of 4 Randomized Clinical Trials. (2016) (0)
P6093Periprocedural safety and long-term efficacy of left atrial appendage closure alone versus combined with other structural or coronary interventions: a dual-centre experience (2017) (0)
Strategies to Optimize Antiplatelet Effects and Minimize Bleeding in NSTE-ACS (2014) (0)
European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. (2023) (0)
THE ROLE OF FEMALE SEX IN THE CONTEMPORARY TREATMENT OF THE LEFT MAIN CORONARY ARTERY INSIGHTS FROM THE W– DELTA (WOMEN– DRUG ELUTING STENT FOR LEFT MAIN CORONARY ARTERY DISEASE) REGISTRY (2013) (0)
Short- Versus Long-TermDual Antiplatelet Therapy AfterDrug-Eluting Stent Implantation (2015) (0)
519 Correlation between endothelial progenitor cells and disease progression in patients with congestive heart failure (2005) (0)
Splanchnic arterial doppler parameters in portal hypertension (1999) (0)
Letter by Cortese and Valgimigli regarding article, "Antithrombotic therapy in patients with chronic kidney disease". (2012) (0)
TCT-272 Everolimus-eluting stent versus bare-metal stent in diabetic patients with ST-segment elevation myocardial infarction. Insights from the EXAMINATION trial (2015) (0)
EnVast Mechanical Thrombectomy After Thrombus Aspiration Failure in a STEMI With a Massive Thrombotic Burden. (2022) (0)
Percutaneous coronary interventions in acute coronary syndromes (2021) (0)
Bleeding risk prediction in elderly patients managed invasively for Acute Coronary Syndromes: external validation of the PRECISE-DAPT and PARIS risk scores (2020) (0)
Selatogrel and other P2Y12 inhibitors' putative off-target effects. (2021) (0)
High-Risk Percutaneous Intervention in the Drug-Eluting Stent Era (2006) (0)
127Validation of high-risk features for stent-related ischaemic events as proposed by the 2017 DAPT guidelines (2018) (0)
Lo studio SORT OUT III (2010) (0)
4181Prognosis of patients with mid-range left ventricular ejection fraction treated with PCI: insight from the global leaders study (2019) (0)
Abstract 2566: Late and Very Late Stent Thrombosis following Elective Drug Eluting Stent Implantation in Unprotected Left Main Coronary Artery: a Multicentre Registry (2007) (0)
Letter by Vranckx and Valgimigli regarding article, "validation of the bleeding academic research consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention". (2012) (0)
Sailing in the complexity of the ‘shark-fin’ sign (2022) (0)
Therapeutic Considerations with Revascularization in Chronic Kidney Disease: Radial Versus Femoral Arterial Access (2020) (0)
TCT-277 Global Differences in Predictors of Long-Term Outcomes After Percutaneous Coronary Intervention: Insights From the XIENCE Pooled Registry (2019) (0)
Expert Answers to Three Key Questions (2008) (0)
058 THE ROLE OF FEMALE SEX IN THE CONTEMPORARY TREATMENT OF THE LEFT MAIN CORONARY ARTERY INSIGHTS FROM THE W-DELTA (WOMEN-DRUG ELUTING STENT FOR LEFT MAIN CORONARY ARTERY DISEASE) REGISTRY (2013) (0)
IMPACT OF RENAL FUNCTION IN PATIENTS WITH HIGH BLEEDING RISK WHO UNDERWENT PERCUTANEOUS CORONARY INTERVENTION WITH XIENCE: A PATIENT-LEVEL POOLED ANALYSIS FROM FOUR XIENCE POST-APPROVAL TRIALS (2019) (0)
Abstract 3658: Favourable One Year Outcome Following Drug Eluting Stent Implantation in Non Bifurcational Lesions Involving Unprotected Left Main Coronary Artery: a Multicenter Registry (2006) (0)
Antithrombotic therapy in patients with atrial fibrillation undergoing PCI remains a moving target, yet with a clearer direction! (2022) (0)
Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry. (2019) (0)
PREDICTIVE ABILITY OF THE PARIS RISK SCORE IN ALL-COMERS PATIENTS UNDERGOING PCI WITH DRUG ELUTING STENTS: EXTERNAL VALIDATION IN THE GLOBAL LEADERS STUDY (2019) (0)
Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry. (2019) (0)
Drawbacks of nonrandomized trials in acute coronary syndromes. (2006) (0)
P6408Potential benefit of ticagrelor monotherapy for patients with hypertension undergoing percutaneous coronary intervention: insights from the Global Leaders trial (2019) (0)
’ s response to reviews Title : Prognostic value of frailty in elderly patients with acute coronary syndrome : A systematic review and meta-analysis (2019) (0)
Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI: A Subgroup Analysis of the BIOSTEMI Randomized Trial. (2020) (0)
CRT-700.27 Valvular Resistance and Bleeding Events Among Patients Undergoing Transcatheter Aortic Valve Replacement (2018) (0)
[The BASKET-PROVE study]. (2011) (0)
COMPARISON OF BLEEDING RISK PREDICTION MODELS WITH DUAL ANTI-PLATELET THERAPY TREATMENT AMONG PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED MEDICALLY WITHOUT REVASCULARIZATION (2019) (0)
Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. (2021) (0)
Trans-radial and Trans-femoral Intervention (2017) (0)
Gallstone ileus in Caroli's disease: Ultrasound diagnosis (1998) (0)
11 Predicting the outcome of reperfusion acutely in patients with STEMI – derivation and validation of the ATI score (2016) (0)
Abstract 12930: Neutrophil Extracellular Traps Correlate With Impaired Myocardial Reperfusion in Patients With St Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention (2014) (0)
IMO 1228 Superior mesenteric artery Doppler impedance indexes in chronic liver diseases (1997) (0)
Clinical practice guidelines of the ESC on myocardial revascularization, 2014 (2015) (0)
Transradial left main PCI is safe and effective. (2018) (0)
Edoxaban in atrial fibrillation with PCI by ACS or stable CAD presentation: a pre-specified analysis of the ENTRUST-AF PCI trial (2020) (0)
TCT-447 Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction. Insights from the EXAMINATION trial (2013) (0)
Transient vs In-Hospital Persistent Acute Kidney Injury in Patients With Acute Coronary Syndrome. (2022) (0)
Complete revascularisation in STEMI: consider the benefits but do not forget the risks! (2019) (0)
SAFETY AND EFFICACY OF 1-MONTH VERSUS 3-MONTH DUAL ANTIPLATELET THERAPY IN HIGH BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS WITH AN EVEROLIMUS ELUTING STENT: INSIGHTS FROM THE XIENCE SHORT DAPT PROGRAM (2021) (0)
Asthma Attack (2021) (0)
Reply (2019) (0)
TCT-425 Rotterdam Radial Access Research: Radial Artery Access Evaluation After Coronary Procedures With Very High Resolution Ultrasound; The Puncture’s Footprint (2015) (0)
4179Cardiovascular outcomes following percutaneous coronary intervention among patients with cancer: observations from a large unselected cohort (2018) (0)
TCT-325 Ultra-Short-Term Evaluation of Coronary Vessel Wall Changes in Reference Segments Adjacent to Culprit Lesions in ST-Segment Elevation Myocardial Infarction (2021) (0)
Intimal Flap Sealing and Healing of Spontaneous Coronary Artery Dissection With Drug-Eluting Balloons. (2021) (0)
Zotarolimus Eluting Stent Clinical Studies (2011) (0)
TCT-753 Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prosthesis (2019) (0)
Reply: Pleiotropic Effects of Ticagrelor Beyond Its Potent Antiplatelet Effects Contributing to Additional Clinical Benefits. (2018) (0)
3331Impact of baseline hemoglobin level and white blood cell count in real-world patients undergoing contemporary percutaneous coronary intervention: insights from the GLOBAL LEADER study (2019) (0)
TCT-273 Influence Of Ticagrelor Versus Clopidogrel On Hemostatic Measurements, Vascular Function And Left Ventricular Remodeling In STEMI Patients (2015) (0)
P2262Long-term safety and efficacy of the xience everolimus eluting stent in patients at high bleeding risk: a patient-level pooled analysis from four xience post-approval trials (2018) (0)
TCT-610 Impact of Baseline Renal Function on the Long-Term Clinical Outcomes After PCI: Insights From a Prespecified Subgroup Analysis of the Randomized GLOBAL LEADERS Trial (2019) (0)
TCT-421 Predicting 2 Years All-Cause Mortality After Contemporary PCI: Revising and Updating the Logistic Clinical SYNTAX Score in the GLOBAL LEADERS Study (2019) (0)
P5500Acute coronary syndrome in young patients: frequency, mechanisms and clinical outcomes following percutaneous coronary intervention (2019) (0)
EXPLORING THE INCREMENTAL VALUE OF CRUSADE SCORE AS CLINICAL GUIDANCE FOR THE DECISION-MAKING OF DUAL ANTIPLATELET THERAPY DURATION: A RETROSPECTIVE ANALYSIS FROM THE (PROLONGING DUAL ANTIPLATELET TREATMENT AFTER GRADING STENT-INDUCED INTIMAL HYPERPLASIA) PRODIGY TRIAL (2015) (0)
TCT-471 Impact of New- versus Early-Generation Drug Eluting Stents in Women according to Age: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. (2016) (0)
Reply: Use of Clinical Risk Score in an Elderly Population: Need for Ad Hoc Validation and Calibration. (2019) (0)
Experts Examine Recent Developments in Interventional Cardiology (2015) (0)
5194Impact of established cardiovascular disease on outcomes in the Global Leaders trial (2019) (0)
Fibrinolytic, antiplatelet, and anticoagulant drugs in acute coronary syndromes (2021) (0)
Ticagrelor in patients with diabetes and previous PCI (2019) (0)
TCT-649 Long-Term Prognosis of Elderly Patients With Additional High Bleeding Risk Factors: A Pooled Analysis From 4 Post-Approval XIENCE Studies (2019) (0)
Atrial Fibrillation on Non-vitamin K Antagonist Oral Anticoagulant Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina (2017) (0)
Clinical utilization of skeletal myoblasts (2006) (0)
5918Influence of intravenous fentanyl versus morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary PCI (2018) (0)
TCT-676 Could the logistic clinical SYNTAX score have predicted the all-cause mortality in the Global Leaders trial? A prediction prior to the unblinding of the trial (2018) (0)
Bivalirudin Versus Unfractionated Heparin for Acute Coronary Syndromes: Do We Have a Winner? (2016) (0)
[Refractory heart failure. Antagonism of tumor necrosis factor alpha and endothelin in humans: 2 promises still to be honored]. (2002) (0)
Radial and Femoral Access in Percutaneous Intervention (2015) (0)
Complete myocardial revascularization: between myth and reality. (2005) (0)
Clinical impact of left atrial appendage filling defects in patients undergoing transcatheter aortic valve implantation. (2021) (0)
TISSUE FACTOR AND COAGULATION FACTOR VII LEVELS DURING ACUTE MYOCARDIAL INFARCTION CONTRIBUTE TO PREDICT MORTALITY AND RE-INFARCTION (2007) (0)
Long-Term Risk of Major Adverse Cardiovascular Events in Patients With Acute Coronary Syndrome: Prognostic Role of Complete Blood Cell Count (2020) (0)
IMPACT OF GEOGRAPHICAL VARIATION BETWEEN EUROPE AND ASIA ON CLINICAL OUTCOMES IN PATIENTS WITH HIGH BLEEDING RISK (HBR) AND BIODEGRADABLE-POLYMER SIROLIMUSELUTING CORONARY STENT: A SUBSTUDY OF MASTER DAPT (2023) (0)
TCT-413 Different Safety Pattern of Ticagrelor Monotherapy Following Percutaneous Coronary Interventions Related to Pulse Pressure Levels: A Subanalysis of the GLOBAL LEADERS Randomized Multicenter Trial (2019) (0)
Guía ESC 2019 sobre el diagnóstico y tratamiento de los síndromes coronarios crónicos (2020) (0)
TCT-304 Long term clinical outcomes in acute coronary syndrome patients at high bleeding risk undergoing PCI with implantation of everolimus-eluting stents: Results from the Patient-Level Pooled Analysis of EES Post Approval Studies. (2018) (0)
Dual antiplatelet therapy for 1 versus 3 months in high bleeding risk patients with or without oral anticoagulant therapy after coronary stenting (2022) (0)
Atrial Interventions (2021) (0)
Is Pretreatment With P 2 Y 12 Inhibitors in Non – ST-Segment – Elevation Acute Coronary Syndrome Clinically Justified ? Pretreatment With P 2 Y 12 Inhibitors in Non – ST-Segment – Elevation Acute Coronary Syndrome Is Clinically Justified (2014) (0)
[The ACUITY trial: one-year results]. (2008) (0)
OP-EHEA190744 1..11 (2019) (0)
Nociceptive Signaling Contributes to Progenitor Cells Activation and Mobilization During Ischemia in Mice and Human Subjects (2012) (0)
ONE VERSUS THREE MONTH DAPT IN HIGH BLEEDING RISK PATIENTS WITH OR WITHOUT CHRONIC KIDNEY DISEASE: RESULTS FROM THE XIENCE SHORT DAPT GLOBAL PROGRAM (2023) (0)
TCT-379 Independent and Combined Effect of Chronic Kidney Disease and Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: Results from a Patient-Level Pooled Analysis of Randomized Controlled Trials (2015) (0)
Glycoprotein IIb/IIIa Inhibitors (2012) (0)
TCT-32 Safety and Efficacy of Biodegradable Polymer Biolimus-Eluting Stents in Patients With Non–ST-Elevation Acute Coronary Syndrome: A Pooled Analysis of GLASSY and TWILIGHT (2021) (0)
P2531Impact of age on clinical outcomes after PCI in patients with ACS and stable CAD treated with 23-month ticagrelor monotherapy following 1-month DAPT in the randomized GLOBAL LEADERS study (2019) (0)
Acceso coronario transradial en pacientes con infarto de miocardio con elevación del segmento ST: estado del arte y perspectivas futuras (2012) (0)
68 Predicting 3-Year Mortality After PCI: Revised Clinical Syntax Model Based on Patient Level Data from 7 Contemporary Stent Trials (2014) (0)
Impact of Preprocedural Computed Tomography on Left Atrial Appendage Closure Success (2023) (0)
Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial". (2021) (0)
Liver transplantation restores systemic and regional circulatory alterations of cirrhosis after a 24 months long follow-up (1998) (0)
CRT-100.49 MOCA I Study - Microvascular Obstruction Treatment Efficacy Measured Using Dynamic Microvascular Resistance (DMVR) — Case Presentation (2020) (0)
Clinical and Procedural Characteristics Associated With Post-Catheterization Radial Artery Occlusion Early Occlusion Late Occlusion (2018) (0)
3DE Anatomy of Normal Aortic Valve and Root. Image Display and Anatomic Correlations (2021) (0)
Assessment of acute myocardial infarction evolution in patients undergoing primary angioplasty or thrombolytic therapy: A gated-SPECT longitudinal evaluation study (2005) (0)
How do you overcome aspirin and P2Y12 blocker resistance in secondary prevention in high-risk patients? (2011) (0)
TCT-398 Impact of Long-Term Ticagrelor Monotherapy Following 1-Month Dual Antiplatelet Therapy in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insights From the Global Leaders Trial (2019) (0)
CRT-200.32 Predicting the Outcome of Reperfusion Acutely in Patients With STEMI - Derivation and Validation of the ATI Score (2016) (0)
IMPACT OF DIABETES MELLITUS ON LONG-TERM OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION WITH DRUG-ELUTING STENT IN A HIGH-BLEEDING RISK POPULATION: OUTCOMES FROM THE POOLED XIENCE REGISTRY (2019) (0)
Complete myocardial revascularization: Between myth and reality [5] (multiple letters) (2005) (0)
P2817Efficacy and safety of ticagrelor monotherapy in patients with complex percutaneous coronary intervention: insights from the Global Leaders trial (2019) (0)
[The SORT OUT III study]. (2010) (0)
EuroPCR highlights 2005. (2005) (0)
TCT-855 Optical coherence tomography appraisal of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing high versus low bivalirudin infusion. The MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study (2018) (0)
P2Y12 inhibitors during and after acute coronary syndrome, where do we stand in 2020? (2020) (0)
TCT-201 Impact of Proton Pump Inhibitors on Efficacy of Antiplatelet Strategies With Ticagrelor or Aspirin After Percutaneous Coronary Intervention (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Marco Valgimigli?

Marco Valgimigli is affiliated with the following schools:

University of Zurich
University of Bologna
University of Ferrara
Aarhus University
University of Amsterdam
University of Messina
University of Ulsan College of Medicine
University of Bristol
University of Perugia
University of Bern